Humanigen (OTC: HGEN)
Humanigen Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Humanigen Company Info
Humanigen, Inc. is a clinical-stage biopharmaceutical company. engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Essex County, NJ.
News & Analysis
What to Do When a Biotech Stock Skyrockets
Fear of missing out can lead investors in this space to hit the buy button at the worst possible times.
Why Humanigen Stock Is Sinking Today
The Food and Drug Administration turned down Emergency Use Authorization of lenzilumab in treating hospitalized COVID-19 patients.
Here's Why Humanigen Is Getting Hammered Today
An attempt to earn authorization for lenzilumab hit a wall at the FDA.
Why This COVID-19 Stock Is On Fire Right Now
While vaccines and diagnostics have been the big winners in the space so far, Humanigen might make investors a lot of money with its drug to treat cytokine storms caused by COVID-19.
2 Top Biotech Stocks to Buy Right Now
One is growing revenue. And the other may soon launch its first product.
Why Humanigen Stock Vaulted Higher Today
Detailed results from a late-stage study of the company's lead candidate were published online.
2 Juicy Biotech Stocks to Consider Buying Right Now
They're both innovating in attractive areas where there's no competition on the radar.
Reddit Traders Can't Get Enough of These 2 Resurgent Biotech Stocks
New coronavirus projects make them easy to hype, but they could face strong headwinds soon.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.